Abstract
The antitumor effect at a distant site of PSK, a Coriolus preparation, was analyzed with the double grafted tumor system in which BALB/c mice received simultaneous intradermal inoculations of Meth‐A tumor in the right (106 cells) and left (2 × 105 cells) flanks and were then injected with PSK in the right‐flank tumor on day 3. PSK inhibited the growth of not only the right but also the left (non‐treated) tumor. Immunized spleen cells were taken from mice which had been cured by the intratumoral administration of 5 mg of PSK and were injected into the Meth‐A tumor on day 3. Adoptive transfer of PSK immunized spleen cells caused the complete regression of Meth‐A tumors. The effector cell activity was lost only after treatment with anti‐Lyt‐1 monoclonal antibody plus complement. Spleen cells and right and left regional lymph node cells prepared from PSK immunized mice were examined for Thy‐1, Lyt‐1, Lyt‐2 and asialo GM1 phenotypes. The number of Lyt‐1‐positive lymphocytes increased in the right regional lymph nodes after intratumoral administration of PSK. A massive accumulation of macrophages and polymorphonuclear leukocytes was found in the right tumor and an infiltration of macrophages and Lyt‐2‐positive lymphocytes was found in the left (non‐treated) tumor by immunohistochemical analyses. These results suggest that intratumoral administration of PSK induces Lyt‐1‐positive cells first in regional lymph nodes, then in the spleen, and subsequently induces macrophages and Lyt‐2‐positive cells in the left (non‐treated) tumor, thus bringing about the regression of metastatic tumors.
Keywords: Antimetastatic effect, Biological response modifier, Intratumoral administration, Tumor immunity
Full Text
The Full Text of this article is available as a PDF (714.4 KB).
References
- 1).Ebina , T. , Kohya , H. , Yamaguchi , T. and Ishida , N.Antimetastatic effect of biological response modifiers in the “double grafted tumor system” . Jpn. J. Cancer Res. (Gann) , 77 , 1034 – 1042 ( 1986. ). [PubMed] [Google Scholar]
- 2).Tsukagoshi , S. , Hashimoto , Y. , Fujii , G. , Kobayashi , H. , Nomoto , K. and Orita , K.Krestin (PSK) . Cancer Treat. Rev. , 11 , 131 – 155 ( 1984. ). [DOI] [PubMed] [Google Scholar]
- 3).Saito , M. , Ichimura , O. , Kataoka , M. , Moriya , Y. , Ueno , K. , Sugawara , Y. , Nanjo , M. and Ishida , N.Pronounced antitumor effect of LAK‐like cells induced in the peritoneal cavity of mice after intraperitoneal injection of OK‐432, a killed Streptococcal preparation . Cancer Immunol. Immunother. , 22 , 161 – 168 ( 1986. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4).Sakamoto , K. , Fujiwara , H. , Nakajima , H. , Yoshioka , T. , Takai , Y. and Hamaoka , T.Requirements of adherent cells for activating Lyt‐1+2− T cells as well as for functioning as antitumor effectors activated by factor(s) from Lyt‐l+2− T cells . Jpn. J. Cancer Res. (Gann) , 77 , 1142 – 1152 ( 1986. ). [PubMed] [Google Scholar]
- 5).Fisher , B. , Saffer , E. A. and Fisher , E. R.Comparison of concomitant and sinecomitant tumor immunity . Proc. Soc. Exp. Biol. Med. , 135 , 68 – 71 ( 1970. ). [DOI] [PubMed] [Google Scholar]
- 6).Bursuker , I. and North , R. J.Suppression of generation of concomitant antitumor immunity by passively transferred suppressor T cells from tumor‐bearing donors . Cancer Immunol. Immunother. , 19 , 215 – 218 ( 1985. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7).North , R. J.The therapeutic significance of concomitant antitumor immunity. I. Lyt‐1+2− T cells from mice with a progressive tumor can cause regression of an established tumor in γ‐irradiated recipients . Cancer Immunol. Immunother. , 18 , 69 – 74 ( 1984. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8).Ogura , T. , Kara , H. , Yokota , S. , Hosoe , S. , Kawase , I. , Kishimoto , S. and Yamamura , Y.Effector mechanism in concomitant immunity potentiated by intratumoral injection of Nocardia rubra cell wall skeleton . Cancer Res. , 45 , 6371 – 6375 ( 1985. ). [PubMed] [Google Scholar]
- 9).Meiss , R. P. , Bonfil , R. D. , Ruggiero , R. A. and Pasqualini , C. D.Histologic aspects of concomitant resistance induced by nonimmunogenic murine tumors . J. Natl. Cancer Inst. , 76 , 1163 – 1175 ( 1986. ). [PubMed] [Google Scholar]
- 10).Nomi , S. , Naito , K. , Kahan , B. D. and Pellis , N. R.Effects of concomitant and sinecomitant immunity on postsurgical metastatis in mice . Cancer Res. , 46 , 6111 – 6115 ( 1986. ). [PubMed] [Google Scholar]
- 11).Gorelik , E. , Segal , S. and Feldman , M.Growth of a local tumor exerts a specific inhibitory effect on progression of lung metastases . Int. J. Cancer , 21 , 617 – 625 ( 1978. ). [DOI] [PubMed] [Google Scholar]
- 12).Gorelik , E. , Segal , S. and Feldman , M.Control of lung metastasis progression in mice: role of growth kinetics of 3LL Lewis lung carcinoma and host immune reactivity . J. Natl. Cancer Inst. , 65 , 1257 – 1264 ( 1980. ). [PubMed] [Google Scholar]
- 13).Gorelik , E. , Segal , S. and Feldman , M.On the mechanism of tumor “concomitant immunity.” Int. J. Cancer , 27 , 847 – 856 ( 1981. ). [DOI] [PubMed] [Google Scholar]
- 14).Fidler , I. J.Optimization and limitations of systemic treatment of murine melanoma metastases with liposomes containing muramyl tripeptide phosphatidylethanolamine . Cancer Immunol. Immunother. , 21 , 169 – 173 ( 1986. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15).De Weger , R. A. , Wilbrink , B. , Moberts , R. M. P. , Mans , D. , Oskam , R. and Otter , W. D.Immune reactivity of SL2 lymphomabearing mice compared with SL2‐immunized mice . Cancer Immunol. Immunother. , 24 , 25 – 36 ( 1987. ). [DOI] [PMC free article] [PubMed] [Google Scholar]